Figure S3. Tau phosphorylated on T123 was present in the nuclei of rat primary neurons. A Neurons (7 DIV) were transfected with IRES-GFP, TAOK2-IRES-GFP or TAOK2 K57A-IRES-GFP, fixed and immunostained with antibodies to detect tau-pT123 (red) and Myc (magenta). Nuclei were counterstained with DAPI (blue). Representative images are shown. Scale bar = 10 μm. (TIF 409 kb
Figure S1. Rac1 mutant peptides have high penetration due to the TAT sequence. (A-C) Representative ...
The effects of IGFBP-3 on the phosphorylation of tau (AT180). To confirm the effect of IGFBP-3 on ph...
Figure S6. AT8+ and TNT2+ tau neurite pathology colocalizes with the axonal marker SMI-312 in the Sc...
Figure S2. Blocking phospho-peptides abolished epitope recognition by TAOK-pS181, tau-pT123 and tau-...
Figure S1. Cp 43 decreased tau phosphorylation in rat primary cortical neurons. A. Quantitative anal...
Table S1. Characteristics of the subjects whose brain tissues were used in this study. PMD refers to...
Figure S1. Western blot results of tau expression in mice expressing pro- or anti-aggregant human ta...
T5x mice exhibit increased levels of Tau phosphorylation and misfolding. (A) The ratio of phosphoryl...
Ac-K274 tau inclusions in human tauopathy brains. (A-C) Representative images of ac-K274 tau immunos...
Representative pThr217 tau pathology in each neurodegenerative disease. A) AD anterior cingulate cor...
Figure S1. Accumulation of soluble, hyperphosphorylated tau in A152T-expressing mice. Figure S2. Inc...
Figure S1. Doxycycline-inducible cell line expressing human mutant P301L tau. Western blot of cell l...
Representative pSer208,210 tau pathology in each neurodegenerative disease. A) AD substantia nigra, ...
Figure S1. Total and phosphorylated soluble tau in hippocampus, cortex and HB. (a, b, c) In the hipp...
Figure S1. Tau misfolding and hyperphosphorylation in human brains with AD and genetic FTLD-Tau-deta...
Figure S1. Rac1 mutant peptides have high penetration due to the TAT sequence. (A-C) Representative ...
The effects of IGFBP-3 on the phosphorylation of tau (AT180). To confirm the effect of IGFBP-3 on ph...
Figure S6. AT8+ and TNT2+ tau neurite pathology colocalizes with the axonal marker SMI-312 in the Sc...
Figure S2. Blocking phospho-peptides abolished epitope recognition by TAOK-pS181, tau-pT123 and tau-...
Figure S1. Cp 43 decreased tau phosphorylation in rat primary cortical neurons. A. Quantitative anal...
Table S1. Characteristics of the subjects whose brain tissues were used in this study. PMD refers to...
Figure S1. Western blot results of tau expression in mice expressing pro- or anti-aggregant human ta...
T5x mice exhibit increased levels of Tau phosphorylation and misfolding. (A) The ratio of phosphoryl...
Ac-K274 tau inclusions in human tauopathy brains. (A-C) Representative images of ac-K274 tau immunos...
Representative pThr217 tau pathology in each neurodegenerative disease. A) AD anterior cingulate cor...
Figure S1. Accumulation of soluble, hyperphosphorylated tau in A152T-expressing mice. Figure S2. Inc...
Figure S1. Doxycycline-inducible cell line expressing human mutant P301L tau. Western blot of cell l...
Representative pSer208,210 tau pathology in each neurodegenerative disease. A) AD substantia nigra, ...
Figure S1. Total and phosphorylated soluble tau in hippocampus, cortex and HB. (a, b, c) In the hipp...
Figure S1. Tau misfolding and hyperphosphorylation in human brains with AD and genetic FTLD-Tau-deta...
Figure S1. Rac1 mutant peptides have high penetration due to the TAT sequence. (A-C) Representative ...
The effects of IGFBP-3 on the phosphorylation of tau (AT180). To confirm the effect of IGFBP-3 on ph...
Figure S6. AT8+ and TNT2+ tau neurite pathology colocalizes with the axonal marker SMI-312 in the Sc...